TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2-and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates

被引:166
作者
Atack, JR [1 ]
Wafford, KA [1 ]
Tye, SJ [1 ]
Cook, SM [1 ]
Sohal, B [1 ]
Pike, A [1 ]
Sur, C [1 ]
Melillo, D [1 ]
Bristow, L [1 ]
Bromidge, F [1 ]
Ragan, I [1 ]
Kerby, J [1 ]
Street, L [1 ]
Carling, R [1 ]
Castro, JL [1 ]
Whiting, P [1 ]
Dawson, GR [1 ]
McKernan, RM [1 ]
机构
[1] Neurosci Res Ctr, Merck Sharp & Dohme Res Labs, Harlow CM20 2QR, Essex, England
关键词
D O I
10.1124/jpet.105.089920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
7-( 1,1-Dimethylethyl)-6-( 2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)3-( 2-fluorophenyl)-1,2,4-triazolo[ 4,3-b] pyridazine ( TPA023) is a triazolopyridazine that binds with equivalent high ( subnanomolar) affinity to the benzodiazepine binding site of recombinant human GABA A receptors containing an alpha 1, alpha 2, alpha 3, or alpha 5 subunit but has partial agonist efficacy at the alpha 2 and alpha 3 subtypes and essentially antagonist efficacy at the alpha 1 and alpha 5 subtypes. In rats, TPA023 gave time- and dose-dependent occupancy after oral dosing, with 50% occupancy corresponding to a dose of 0.42 mg/ kg. It has anxiolytic-like activity in unconditioned ( elevated plus maze) and conditioned ( fear-potentiated startle and conditioned suppression of drinking) rat models of anxiety with minimum effective doses ( MED; 1-3 mg/ kg) corresponding to 70 to 88% occupancy. However, there was no appreciable sedation in a response sensitivity ( chain-pulling) assay at a dose of 30 mg/ kg, resulting in 99% occupancy. Similarly, TPA023 was robustly anxiolytic in the squirrel monkey conditioned emotional response assay, with a MED of 0.3 mg/ kg, but did not produce any sedation in a lever-pressing test of sedation even at 10 mg/ kg. TPA023 produced no impairment in performance in the mouse Rotarod assay, and there was only a mild interaction with ethanol. In addition to anxiolytic-like efficacy, TPA023 had anticonvulsant activity in a mouse pentylenetetrazole seizure model. Finally, TPA023 did not cause precipitated withdrawal in mice treated for 7 days with the nonselective agonist triazolam, nor did N-methyl-beta-carboline-3- carboxamide ( FG 7142) precipitate withdrawal in mice treated for 7 days with TPA023. In summary, the novel alpha 2/alpha 3-selective efficacy profile of TPA023 translates into a nonsedating anxiolytic profile that is distinct from nonselective agonists.
引用
收藏
页码:410 / 422
页数:13
相关论文
共 40 条
  • [1] The use of benzodiazepines in anxiety and other disorders
    Argyropoulos, SV
    Nutt, DJ
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1999, 9 : 407 - 412
  • [2] Anxioselective Compounds Acting at the GABAA Receptor Benzodiazepine Binding Site
    Atack, John R.
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2003, 2 (04) : 213 - 232
  • [3] Anxiogenic properties of an inverse agonist selective for α3 subunit-containing GABAA receptors
    Atack, JR
    Hutson, PH
    Collinson, N
    Marshall, G
    Bentley, G
    Moyes, C
    Cook, SM
    Collins, I
    Wafford, K
    McKernan, RM
    Dawson, GR
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (03) : 357 - 366
  • [4] Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for α1 versus α2 and α3 subunit-containing GABAA receptors
    Atack, JR
    Smith, AJ
    Emms, F
    McKernan, RM
    [J]. NEUROPSYCHOPHARMACOLOGY, 1999, 20 (03) : 255 - 262
  • [5] Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders
    Ator, NA
    [J]. CNS SPECTRUMS, 2005, 10 (01) : 31 - 39
  • [6] Comparison of benzodiazepine (BZ) receptor agonists in two rodent activity tests
    Bayley, PJ
    Bentley, GD
    Jackson, A
    Williamson, D
    Dawson, GR
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 1996, 10 (03) : 206 - 213
  • [7] Pharmacological characterization of a novel cell line expressing human α4β3δ GABAA receptors
    Brown, N
    Kerby, J
    Bonnert, TP
    Whiting, PJ
    Wafford, KA
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (07) : 965 - 974
  • [8] 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine:: A functionally selective γ-aminobutyric acidA (GABAA) α2/α3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models
    Carling, RW
    Madin, A
    Guiblin, A
    Russell, MGN
    Moore, KW
    Mitchinson, A
    Sohal, B
    Pike, A
    Cook, SM
    Ragan, IC
    McKernan, RM
    Quirk, K
    Ferris, P
    Marshall, G
    Thompson, SA
    Wafford, KA
    Dawson, GR
    Atack, JR
    Harrison, T
    Castro, JL
    Street, LJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) : 7089 - 7092
  • [9] An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA α5 receptors with cognition enhancing properties
    Chambers, MS
    Atack, JR
    Carling, RW
    Collinson, N
    Cook, SM
    Dawson, GR
    Ferris, P
    Hobbs, SC
    O'Connor, D
    Marshall, G
    Rycroft, W
    MacLeod, AM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (24) : 5829 - 5832
  • [10] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099